Publications by authors named "Ming-Hua Shao"
Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma.
World J Gastrointest Surg
September 2024
Article Synopsis
- - The study explores the effectiveness and safety of combining transarterial chemoembolization (TACE) with the immunotherapy drug tislelizumab, and potentially targeted therapy, for treating unresectable hepatocellular carcinoma (HCC) in a real-world environment.
- - Results from 56 patients show that the median progression-free survival (PFS) was 14 months, and overall survival (OS) was 28 months, with high response rates of 82.14% and disease control rates of 87.50%.
- - The findings suggest this treatment combination is particularly effective in patients who have not previously received immunotherapy, although some patients experienced significant side effects like elevated liver enzymes.